Clinical Trial Update: A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the durability of response and safety of nemolizumab for 24 weeks in participants with prurigo nodularis; results have been posted foll…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prurigo Nodularis

Drugs mentioned

• Nemolizumab (nemolizumab)

Snippet

Sponsor: Galderma R&D | Conditions: Prurigo Nodularis | Phase 3 | Status: COMPLETED | Results posted: 2024-10-08